N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
C07K 14/35 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
The disclosure provides methods and related kits, reagents, and systems for selectively deaminating unmethylated cytosine residues in nucleic acid molecules. In some embodiments, the methods and related kits, reagents, and systems are applied for methods of detecting and/or mapping methylated cytosine residues in nucleic acids. The nucleic can be RNA or DNA. Some embodiments include contacting the polynucleic acid with a bacterial cytosine deaminase, for example DddA or SsdA, or functional fragments or derivatives thereof. Representative DddA and SsdA have sequences set forth in SEQ ID NOS:1 and 2, respectively. The bacterial cytosine deaminases of the disclosure are sensitive to methylation and, thus, deaminate only unmethylated cytosines to provide a cytosine to uracil conversion. The conversion can be detected as a C•G-to-T•A transitions in subsequent sequencing analysis.
Described herein is an oral sampling device, as well as methods of making and using the oral sampling device. The oral sampling device is configured to be placed inside of a human mouth to capture an analyte(s) found in bodily fluid, such as saliva, produced within the mouth. An example oral sampling device includes a body, at least a portion of which is sized to fit inside of a mouth of a human, has an outer surface, and a recess(es) defined in the outer surface to capture the analyte(s) therein. In some examples, a material of the body within the recess was subjected to a surface treatment to promote the capture of the analyte(s). In some examples, the oral sampling device includes a flavored substance disposed on at least the portion of the body that is to be received inside of a human mouth.
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
5.
AUTOMATED DISPENSER FOR CASTING HIGH-VISCOSITY SCAFFOLD SOLUTIONS
A viscous material dispenser, including an extruder with an inlet, a barrel, and a nozzle, a pump configured to fit inside the barrel, a tube connected to the inlet, a first valve attached to a first arm of the tube, and a second valve attached to a second arm of the tube, where when the first valve is open and the second valve is closed, the plunger is depressed by the source of pressurized air, causing a viscous material to flow out of the nozzle. Further, a method of dispensing a viscous material using a viscous material dispenser including positioning a substrate underneath the nozzle, filling the barrel of the extruder with a viscous material, and dispensing the viscous material from the nozzle of the extruder and onto the substrate by opening the first valve and closing the second valve.
B65D 83/00 - Containers or packages with special means for dispensing contents
B05C 17/015 - Hand tools or apparatus using hand-held tools, for applying liquids or other fluent materials to, for spreading applied liquids or other fluent materials on, or for partially removing applied liquids or other fluent materials from, surfaces for discharging material through an outlet orifice by pressure with pneumatically actuated piston or the like
B65D 83/64 - Contents and propellant separated by piston
The present disclosure provides for the treatment of cardiac diseases and disorders using in vitro-differentiated cardiomyocytes. Such methods can take advantage of both autologous and allogeneic pluripotent stem cells.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
7.
Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
8.
SYNTHETIC INTERMEDIATES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR IMMUNE CELL THERAPIES
SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (USA)
Inventor
Sellers, Drew
Cardle, Ian
Abstract
Example compositions, systems, devices, and methods are used for universal chimeric antigen receptor T (UCAR-T) cell therapy. An example method includes administering, to a subject, engineered immune cells that express a chimeric antigen receptor (CAR) including an extracellular component and an intracellular component linked by a transmembrane domain, wherein the extracellular component includes an intermediary-binding domain. The example method further includes administering, to the subject, a synthetic intermediary including a tag linked to an antigen binding domain, the tag specifically binding the intermediary-binding domain, the antigen binding domain specifically binding an antigen expressed on a surface of a target cell in the subject.
The Chancellor, Masters And Scholars Of The University Of Oxford (United Kingdom)
The Institute of Cancer Research: Royal Cancer Hospital (United Kingdom)
University of Washington (USA)
Inventor
Islam, Md. Saiful
Tumber, Anthony
Schofield, Christopher
Paschalis, Alec
Welti, Jonathan
Sharp, Adam
De Bono, Johann
Plymate, Stephen
Abstract
The invention relates to methods for treating prostate cancer by targeting the generation of splice variants of the androgen receptor. In one aspect, this can be achieved by targeting JMJD6 to reduce the production of androgen receptor splice variants. The invention finds particular use in the treatment of prostate cancer that is resistant to conventional androgen therapy.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A capacitive sensor system configured to measure capacitance, including a sample volume, a sample capacitive sensor configured to measure the capacitance of the sample volume without physical contact between the sample capacitive sensor and the sample volume, a control capacitive sensor, a differential sensing subsystem configured to measure a control sensor volume using the control capacitive sensor, and electrical circuitry connected to both the control capacitive sensor and the sample capacitive sensor.
G01F 23/263 - Indicating or measuring liquid level or level of fluent solid material, e.g. indicating in terms of volume or indicating by means of an alarm by measuring physical variables, other than linear dimensions, pressure or weight, dependent on the level to be measured, e.g. by difference of heat transfer of steam or water by measuring variations of capacity or inductance of capacitors or inductors arising from the presence of liquid or fluent solid material in the electric or electromagnetic fields by measuring variations in capacitance of capacitors
G01N 33/487 - Physical analysis of biological material of liquid biological material
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
11.
METHODS AND COMPOSITIONS FOR T CELL DIFFERENTIATION
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the same. Further described herein are immune cells differentiated using stromal -free methods and compositions comprising such immune cells. In some embodiments, the immune cells can be genetically modified. In some embodiments, the immune cells or compositions comprising said immune cells can be administered to a patient as a cellular replacement therapy to treat a condition.
Manoparticies that display clade la, clade lb, and clade 3 sarbecovirus receptor-binding domains and compositions thereof are provided, together with pharmaceutical compositions thereof and methods for using the nanoparticles and compositions to treat or limit Sarbecovirus infection.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
13.
METHODS AND SYSTEMS FOR LARGE SCALE SCAFFOLDING OF GENOME ASSEMBLIES
Computational methods used for large scale scaffolding of a genome assembly are provided. Such methods may include a step of applying a location clustering model to a test set of contigs to form two or more location cluster groups, each location cluster group comprising one or more location-clustered contigs; a step of applying an ordering model to each of the two or more location cluster groups to form an ordered set of one or more location-clustered contigs within each cluster group; and a step of applying an orienting model to each ordered set of one or more location-clustered contigs to assign a relative orientation to each of the location-clustered contigs within each location cluster group. In some aspects, the test set of contigs are generated from aligning a set of reads generated by a chromosome conformation analysis technique (e.g., Hi-C) with a draft assembly, a reference assembly, or both.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
Apparatuses, systems, and methods for synthetic 3D digital microscopy image sets. A microscope captures a depth stack of a sample using a first labelling technique. A trained machine learning model generates a synthetic depth stack of images based on the imaged depth stack. The synthetic depth stack mimics the appearance of a second labelling technique, which is targeted to a tissue structure of interest. A segmentation mask is generated based on the synthetic depth stack. The machine learning model may be trained on depth stacks of samples prepared with both the first and the second labelling techniques.
Disclosed are de novo designed polypeptide agonists and antagonists of IL-21, conditionally-active IL-21 agonists and antagonists, and methods for using them to treat cancer or to modulate an immune response.
The present disclosure provides a device for respiratory protection. The device includes a face shield having a first end and a second end opposite the first end. The device also includes a headband coupled to the first end of the face shield and the second end of the face shield. The device also includes an electrohydrodynamic (EHD) air filter system positioned along an entirety of a perimeter of the face shield.
Described herein are reprogrammable systems and methods for controlling the same. The reprogrammable system comprises a first side configured to be reprogrammable in at least a first direction. The first side is formed by a reprogrammable structure having one or more layers stacked in a second direction. An individual layer of the one or more layers has repeating unit cells. A first unit cell of the repeating unit cells has elements. The elements are connected by connecting joints. A first unit cell of the repeating unit cells shares at least one element and/or at least one connecting joint with a second unit cell of the repeating unit cells.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Disclosed herein are designed heterodimer proteins, monomeric polypeptides capable of forming heterodimer proteins, protein scaffolds including such polypeptides, and methods for using the heterodimer proteins and subunit polypeptides for designing logic gates.
G06N 3/00 - Computing arrangements based on biological models
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
H03K 19/00 - Logic circuits, i.e. having at least two inputs acting on one output; Inverting circuits
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Method and system for forming of microcellular bubbles within a thermoplastic member employ an energy beam to form the microcellular bubbles within a selected portion of the thermoplastic member. A method includes infusing the thermoplastic member with a gas to form a gas-infused thermoplastic member and transmitting an energy beam onto the selected portion of the gas-infused thermoplastic member to induce subsurface heating of the selected portion of the gas-infused thermoplastic member to form microcellular bubbles within the selected portion of the gas-infused thermoplastic member.
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventor
Fujise, Ken
Pinkaew, Decha
Blagg, Brian
Serwetnyk, Michael
Brackett, Christopher M.
Zuo, Ang
Halim, Hasseri
Abstract
Described herein is the development of ureas and thioureas as small molecular weight fortilin inhibitors. Small molecular weight compounds that inhibit fortilin, as well as compositions, and methods for using same, described herein ameliorate atherosclerosis by targeting fortilin, not hypercholesterolemia or lipid metabolism. This contrasts with the majority of anti-atherosclerosis therapies that rely on lipid lowering and modification. The data presented herein show that the inhibition of fortilin leads to the polarization of macrophages to the anti-inflammatory, anti-atherosclerotic, M2 phenotype. These inhibitors can be used to treat atherosclerosis as well as fortilin-associated cancers.
C07C 243/18 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
C07C 335/16 - Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
The present disclosure provides a method of analyzing the structure of a glycan sample, the method including: receiving data indicative of one or more spectra of mass-to-charge ratio (m/z) versus relative abundance of the glycan sample from a mass spectrometer (MS) instrument; generating a ratio according to the following Equation:
The present disclosure provides a method of analyzing the structure of a glycan sample, the method including: receiving data indicative of one or more spectra of mass-to-charge ratio (m/z) versus relative abundance of the glycan sample from a mass spectrometer (MS) instrument; generating a ratio according to the following Equation:
a
a
+
b
The present disclosure provides a method of analyzing the structure of a glycan sample, the method including: receiving data indicative of one or more spectra of mass-to-charge ratio (m/z) versus relative abundance of the glycan sample from a mass spectrometer (MS) instrument; generating a ratio according to the following Equation:
a
a
+
b
wherein a is a magnitude of one or more first peaks in the one or more spectra and b is the magnitude of one or more second peaks in the one or more spectra; determining that the ratio is within a range of a predetermined ratio; based on determining that the ratio is within the range of the predetermined ratio, determining that a predetermined structural characteristic is present in the glycan sample; and outputting an indication of the predetermined structural characteristic in the glycan sample.
Seattle Children's Hospital d/b/a Seattle Children's Research Institute (USA)
Inventor
King, Daniel
Hannaford, Blake
Li, Yangming
Adidharma, Lingga
Bly, Randall
Abuzeid, Al-Waleed M.
Moe, Kristen S.
Abstract
A method includes accessing training images that collectively depict multiple stages of a surgical procedure. The method also includes accessing labels that indicate, for each of the training images, characteristics of one or more surgical tools depicted and a stage of the multiple stages of the surgical procedure depicted. The method also includes training a computational model, using the training images and the labels, to associate runtime images with a stage of the multiple stages based on characteristics of one or more surgical tools that are depicted by the runtime images. Another method includes associating, using a computational model, runtime images with a stage of a surgical procedure based on characteristics of one or more surgical tools depicted by the runtime images and generating output that indicates the stage associated with each of the runtime images.
G06N 3/088 - Non-supervised learning, e.g. competitive learning
G06T 7/70 - Determining position or orientation of objects or cameras
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G16H 70/20 - ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
26.
COMPOSITIONS INCLUDING ENDOPHYTES FOR IMPROVING PLANT NUTRITION, GROWTH,AND PERFORMANCE AND METHODS OF USING THE SAME
Endophyte inoculant compositions, methods of making such compositions, methods of using such compositions, and physiologically altered plants treating with such compositions are disclosed. The endophyte inoculant composition may include one or more of endophyte strains WW5, WW6, WW7, and PTD1, which promote plant mineral nutrient acquisition and uptake, vigor, health, growth, and yield when applied to non-native host plants.
Systems and methods of identifying medical disorders in one or more subjects are disclosed herein. In one embodiment, sound is transmitted toward a subject and at least a portion of the sound reflected by the subject and is acquired as echo data. The acquired echo data is used to generate a motion waveform having a plurality of peaks detected therein. At least a portion of the plurality of peaks may be indicative of movement of the subject. One or more medical disorders in the subject can be identified based on, for example, time durations and/or amplitude changes between peaks detected in the motion waveform.
Methods for nanopore-based protein analysis are provided. The methods address the characterization of a target protein analyte, which has a dimension greater than an internal diameter of the nanopore tunnel, and which is also physically associated with a polymer. The methods further comprise applying an electrical potential to the nanopore system to cause the polymer to interact with the nanopore tunnel. The ion current through the nanopore is measured to provide a current pattern reflective of the structure of the portion of the polymer interacting with the nanopore tunnel. This is used as a metric for characterizing the associated protein that does not pass through the nanopore.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Silva Manzano, Daniel Adriano
Yu, Shawn
Ulge, Umut
Baker, David
Garcia, Kenan Christopher
Spangler, Jamie
Walkey, Carl
Rubio, Alfredo Quijano
Jude, Kevin
Weitzner, Brian
Abstract
De novo designed polypeptides that bind to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγc heterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
The present disclosure provides a device comprising a catheter having a first end and a second end opposite the first end. The catheter includes a first lumen, a second lumen, and a third lumen. The first lumen is configured to receive a guidewire therethrough to position the device in a desired anatomy. The device includes a needle movably positioned within the second lumen of the catheter. The needle includes a first end and a second end opposite the first end, and the needle is hollow such that the needle includes a lumen extending from the first end to the second end. The needle is configured to transition from a first position in which the first end of the needle is positioned entirely within the second lumen of the catheter to a second position in which the first end of the needle extends out of the second lumen of the catheter.
The present technology relates generally to systems and methods for mediated-reality surgical visualization. A mediated-reality surgical visualization system includes an opaque, head-mounted display assembly comprising a frame configured to be mounted to a user's head, an image capture device coupled to the frame, and a display device coupled to the frame, the display device configured to display an image towards the user. A computing device in communication with the display device and the image capture device is configured to receive image data from the image capture device and present an image from the image data via the display device.
H04N 13/344 - Displays for viewing with the aid of special glasses or head-mounted displays [HMD] with head-mounted left-right displays
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
H04N 13/239 - Image signal generators using stereoscopic image cameras using two 2D image sensors having a relative position equal to or related to the interocular distance
32.
BIOPLASTIC MATERIALS OBTAINED FROM BIOLOGICAL MATTER
Bioplastic compositions and methods of making are described herein. The various mechanical and physical properties of the bioplastic may be varied by altering the thermoforming or incorporating an additive depending on the desired mechanical and physical properties of the end product. The bioplastic may be made entirely of biomatter and be backyard compostable.
A biological cement including algal biomatter, cement, and water. The present disclosure also provides methods of preparing the biological cement. The biological cement can be used in place of traditional cement, for instance by being incorporated into mortar or concrete for structural or other applications. The algal biomatter may include one or more of biomass from Chlorella, Spirulina (Arthrospira platensis), Saccharina latissima, Ulva spp. (such as U. lactuca or U. expensa), Agarophyton, Sargassum, Gracilaria parvispora, Halymenia hawaiiana or Caulerpa lentillifera.
C04B 28/14 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing calcium sulfate cements
C04B 40/02 - Selection of the hardening environment
T. pallidumT. pallidumT. pallidumT. pallidum is present in the sample. The disclosed elements can be used for clinical tests to determine whether the patient has syphilis as the basis for further clinical testing or treatment of syphilis.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Various devices, systems, and methods for performing personalized dosimetry of a patient receiving a radiopharmaceutical are described. In an example method, anatomic data is generated by performing a computed tomography (CT) scan on the patient when they are lying down and wearing a garment. Based on the anatomic data, locations of organs of the patient are determined with respect to one or more fiducial markers integrated with the garment. Detectors for detecting photons from a radiopharmaceutical are placed on the garment based on locations of the organs. Subsequently, the patient may be administered a dose of the radiopharmaceutical. When the patient wears the garment, the detectors may detect photons released from the decaying radiopharmaceutical that is distributed in the organs. The radiation dosage to the organs may be determined based on the detected photons.
The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Compositions and methods for modular fabrication of large, three-dimensional, perfusable networks of vascularized tissue are provided. Each layer within the tissue may include the same or different cell types and have the same or different types of vasculature. In some aspects layers of tissue together form the large, three-dimensional perfusable networks as each layer contains a portion of the larger tissue and the combination of the various layers creates a tertiary structure of integrated perfusable networks that exhibit remodeling and evenly distributed perfusion among layers while maintaining a patterned open-lumen architecture.
Embodiments of the present disclosure provide compositions and methods for injectable recombinant protein-based hydrogels for therapeutic delivery. Embodiments of the composition and methods comprise a recombinant protein, a cell consortia, and a biocompatible medium. The recombinant protein comprises one or more self-association domains and a flexible linker comprising a pseudorepeat of amino acids, forming stable hydrogels in contact with the cell consortia. Such composition and methods have broad application in delivery of viable cells to a biological tissue for tissue repair and regeneration.
A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
In some embodiments, a computer-implemented method of enhancing sequence read data from a cell-free DNA (cfDNA) sample from a subject for predicting a pregnancy-related condition is provided. A computing system determines a coverage profile based on sequence read data for a plurality of informative sites associated with specific tissue types, cell types, or cell states. The computing system generates a prediction of a presence of or an absence of the pregnancy-related condition by providing at least features from a set of features based on a predicted fetal fraction and a set of features based on the coverage profile as input to at least one machine learning model trained to predict a probability of future onset of the pregnancy-related condition based on the features. In some embodiments, a computer-implemented method of enhancing sequence read data for predicting fetal fraction is provided.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
41.
FUNCTIONALIZED CHROMOPHORIC POLYMER DOTS AND BIOCONJUGATES THEREOF
The present invention provides, among other aspects, functionalized chromophoric polymer dots comprising a hydrophobic core and a hydrophilic cap, and bioconjugates thereof. Also provided are improved methods for preparing functionalized chromophoric polymer dots. Methods for in vivo imaging and molecular labeling are also disclosed.
A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided
C08G 69/48 - Polymers modified by chemical after-treatment
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/67 - General methods for enhancing the expression
Disclosed herein are ceramic selective membranes and methods of forming the ceramic selective membranes by forming a selective silica ceramic on a porous membrane substrate.
H01M 8/1053 - Polymer electrolyte composites, mixtures or blends consisting of layers of polymers with at least one layer being ionically conductive
H01M 8/1062 - Polymeric electrolyte materials characterised by a porous support having no ion-conducting properties characterised by the physical properties of the porous support, e.g. its porosity or thickness
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
H01M 8/106 - Polymeric electrolyte materials characterised by a porous support having no ion-conducting properties characterised by the chemical composition of the porous support
H01M 8/1016 - Fuel cells with solid electrolytes characterised by the electrolyte material
H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
Apparatuses and methods for measuring total blood volume with ultrasound are disclosed. In one embodiment, a system for monitoring a blood volume of a patient includes an ultrasound transmitter configured for emitting an ultrasound toward a target blood vessel of the patient; and an ultrasound receiver configured for receiving the ultrasound reflected from the target blood vessel of the patient. The system also includes, a controller configured for: determining an expanded state of the blood vessel based on the ultrasound reflected from the target blood vessel; determining a collapsed stated of the blood vessel based on the ultrasound reflected from the target blood vessel; and determining the blood volume of the patient based on the ratio of the collapsed stated and the expanded stated of the blood vessel.
In some embodiments, a molecular tagging system that uses synthetic DNA-based tags is provided. In some embodiments, a kit for tagging objects with molecular tags is provided that comprises a plurality of molbit reservoirs. Each molbit reservoir is associated with a molbit and includes nucleic acid molecules that represent the molbit. In some embodiments, a method is provided wherein a digital tag value is determined, the digital tag value is converted to a molbit tag value, nucleic acid molecules associated with each molbit value indicated as present in the molbit tag value are combined, and the combined nucleic acid molecules are applied to an object to tag the object. In some embodiments, a system is provided that includes a computing system configured to receive raw nanopore signals from a sequencing device, to identify molbits based on the signals, and to determine a digital tag based on the identified molbits.
Overexpressed proteins associated with inflammatory adipocytes have been demonstrated in TNF-a inflamed adipocyte lines derived from humans and mice as well as in visceral fat derived from mice fed an inflammatory-generating high fat high sucrose diet. The adipocyte-associated proteins are immunogenic in humans and mice, and can be used as a vaccine that drives Type II T-cells to inflammatory adipose tissue. Compositions and methods for the prevention and treatment of disease associated with metabolic obesity, including cancer, such as breast cancer, and non-alcoholic fatty liver disease (NAFLD) are provided.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
47.
SYSTEM AND METHOD TO DIRECT THE DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED ODONTOBLASTS
The technology as described herein relates to discovery of methods for generating odontoblasts or organoids thereof in vitro and compositions that utilize the generated odontoblasts for restoringtooth structure.
Systems and methods to link CD40 signaling to antigen binding, independently of CD40 ligand binding are described. The systems and methods include fusion proteins including an extracellular antigen binding domain linked to an intracellular CD40 signaling domain.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present disclosure provides methods, systems, and kits for quantifying lipoprotein(a) based on measuring selected proteotypic peptide(s). The methods of the disclosure are also useful in determining if a subject is at risk to develop cardiovascular disease. The disclosure also provides methods of determining a reference amount of selected proteotypic peptide(s) in a reference sample.
Disclosed are kinetically-controlled RNA biosensor constructs and related, nucleic acids, vectors, cells, systems and methods useful for detecting ligands of interest. Also disclosed are computer implemented methods for designing kinetically-controlled biosensors, guide RNA molecules, and/or target promoter sequences, and constructs produced thereby. Exemplary embodiments include scRNAs and expression cassettes incorporating synthetic promoters for implementation of CRISPRa.
G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/94 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics
51.
PROTEIN-BASED COMPOSITION FOR ADDITIVE MANUFACTURING
Universidad del Pais Vasco/Euskal Herriko Unibersitatea (Spain)
Inventor
Nelson, Alshakim
Sánchez Rexach, Eva
Sardon, Haritz
Abstract
Disclosed herein are compositions comprising globular proteins and diacrylate-containing compounds that can react in-situ to provide polymerized networks that can be formed into objects using additive manufacturing techniques, such as printing techniques that use vat photopolymerization. Objects printed using the disclosed compositions also are described, with embodiments of such objects exhibiting shape recovery behavior. Also disclosed are methods of making and using the disclosed compositions.
C09D 4/00 - Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond
C09D 189/00 - Coating compositions based on proteins; Coating compositions based on derivatives thereof
Materials, methods, and systems for biorthogonal ligation of hydrogel labels to crosslinked-natural polymer hydrogels are provided. A heterobifunctional linker includes a peptide-reactive activated functional group on the heterobifunctional linker, including an activated amine-reactive functional group, an activated thiol-reactive functional group and being reactive with a hydrogel comprising a crosslinked natural polymer. The heterobifunctional linker also includes a photocaged reactive group including a photocaged hydroxylamine, a photocaged alkoxyamine, a photocaged hydrazide, a photocaged amine, a photocaged tetrazine, or a photocaged alkyne-containing moiety. The peptide-reactive activated functional group does not include an azide.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
54.
WETTING AND FRACTURE INDUCED COMPOSITES FOR HIGHLY SENSITIVE RESISTIVE AND CAPACITIVE SENSORS
A sensor, comprising including a composite substrate including a template material, where the template material includes a plurality of insulating fibers, and a plurality of carbon nanotubes bonded to the insulating fibers forming a nanotube coating on the insulating fibers, and where the composite substrate exhibits a tensional fracture induced by a unidirectional tensile force to the composite substrate, wherein the plurality of insulating fibers align along the tensile force and expand in an out-of-plane direction at the site of the fracture, a first electrode coupled to the nanotube coating on one side of the fracture, and a second electrode coupled to the nanotube coating on the opposite side of the fracture, such that an electrical signal applied between the first electrode and the second electrode passes through the plurality of junctions at the site of the fracture.
A61B 5/263 - Bioelectric electrodes therefor characterised by the electrode materials
D21H 17/67 - Water-insoluble compounds, e.g. fillers or pigments
D21H 21/14 - Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
D21H 27/00 - Special paper not otherwise provided for, e.g. made by multi-step processes
D21H 19/68 - Coatings characterised by a special visual effect, e.g. patterned or textured uneven, broken or discontinuous
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
D06M 23/16 - Processes for the non-uniform application of treating agents, e.g. one-sided treatment; Differential treatment
D06M 11/05 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with boranes, diboranes, silanes, disilanes, phosphines, diphosphines, stibines, distibines, arsines or diarsines or complexes thereof with heavy water
G01L 1/18 - Measuring force or stress, in general using properties of piezo-resistive materials, i.e. materials of which the ohmic resistance varies according to changes in magnitude or direction of force applied to the material
G01L 1/14 - Measuring force or stress, in general by measuring variations in capacitance or inductance of electrical elements, e.g. by measuring variations of frequency of electrical oscillators
55.
POLYMER-SILICA HYBRID PDOTS AND METHODS OF USE THEREOF
The present disclosure provides organic-inorganic hybrid polymer particles, which have desirable surface chemistry and optical properties that make them particularly suitable for biological and optical applications. The present disclosure also provides methods of making organic-inorganic hybrid polymer particles. The present disclosure also provides methods of using the organic-inorganic hybrid polymer particles for biological and optical applications.
H01B 1/18 - Conductive material dispersed in non-conductive inorganic material the conductive material comprising carbon-silicon compounds, carbon, or silicon
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
G02F 1/015 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on semiconductor elements with at least one potential jump barrier, e.g. PN, PIN junction
56.
BARCODED INFLUENZA VIRUSES AND DEEP MUTATIONAL SCANNING LIBRARIES INCLUDING THE SAME
Methods to create barcoded influenza viruses without disrupting the function of the viral proteins and the proper packaging of the viral genome segments are described. The barcoded influenza viruses can be used within deep mutational scanning libraries to map influenza resistance mutations to therapeutic treatments. The libraries can also be used to predict influenza strains that may become resistant to therapeutic treatments and/or more easily evolve to infect new species. The libraries include features that allow efficient collection and assessment of informative data, obviating bottlenecks of previous approaches.
ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOMATERIALES - CIC BIOMAGUNE (Spain)
UNIVERSITY OF THE BASQUE COUNTRY, UPV/EHU (Spain)
Inventor
Nelson, Alshakim
Sánchez Rexach, Eva
Sadaba, Naroa
Yu, Siwei
Sardón Muguruza, Haritz
De Aberasturi, Dorleta Jiménez
Liz-Marzan, Luis Manuel
Abstract
Shape-restoring materials, as well as techniques for generating shape-restoring materials, are described. An example method includes generating a construct by exposing, to UV-visible light, a resin comprising a globular protein, a water-soluble co-monomer, light-to-heat converting nanoparticles, water, and a photoinitiator. At least a portion of the water is removed from the construct. The construct is converted from a first shape to a second shape by applying a force to the construct. The construct is reverted to the first shape in response to being exposed to NIR light, due to the absorption of the NIR light by the nanoparticles.
The present disclosure is directed to relates to systems and methods for evaluating tissue using high intensity focused ultrasound (HIFU) energy. In one embodiment, for example, a system for treating a patient comprises an ultrasound source configured to deliver HIFU energy to a target tissue mass of the patient and a function generator operably coupled to the ultrasound source for initiating a pulsing protocol for delivering the HIFU energy. The system further comprises a controller configured to perform operations comprising applying HIFU energy to induce cavitation in the target tissue mass and cause a biomarker to be released, comparing a baseline concentration of the biomarker from a first fluid sample to a concentration of the biomarker in a second fluid sample within 2 hours after applying HIFU, and repeating the applying and comparing until the concentration of the biomarker in the fluid sample falls below a threshold value.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
Methods and kits for assessing and partially or uniquely identifying proteins, such as in complex mixtures of proteins and other molecules/structures, are described. In an embodiment, the methods include combinatorially barcoding target amino acid residues on the protein and, in certain embodiments, enzymatically cleaving the protein, such as before and after rounds of combinatorial barcoding. In an embodiment, the methods include (a) attaching a first nucleic acid molecule to target amino acid residues in the plurality of proteins in the sample to provide nascent nucleic acid tags at the target amino acid residues; (b) performing one or more rounds of split-pool barcoding to provide mature nucleic acid tags at the target amino acid residues (c) sequencing the mature nucleic acid tags; and (d) determining a frequency of the target amino acid residues in one or more protein of the plurality of proteins.
Polypeptides including the amino acid sequence of SEQ ID NO:78-80, substituted with one or more sequon, are provided, as are fusion proteins and nanoparticles formed from such polypeptides, and methods for their use.
Methods and systems for creating patterns in tissue growth for tissue engineering are disclosed. In one embodiment, a method for arranging biological cells along predetermined patterns using an ultrasound includes: emitting the ultrasound by an ultrasound transducer; transmitting the ultrasound through a holographic lens toward a plurality of cells; and generating a pressure field in the predetermined patterns. The predetermined pattern includes a plurality of mutually parallel transverse planes. The parallel transverse planes are configured to entrap groups of cells of the plurality of cells. The axial pressure gradients within the parallel transverse planes are smaller than a first predetermined threshold. The lateral pressure gradients within the parallel transverse planes are larger than a second predetermined threshold. In response to generating the pressure field, the groups of entrapped cells are aligned within parallel transverse planes.
An edge device can include a processing device, an image sensor, and a memory having instructions that are executable by the processing device for causing the processing device to perform operations. The processing device can receive, from the image sensor, an image of an environment. The processing device can determine a visibility measure corresponding to the environment by determining a dark channel of the image, determining, based on the dark channel of the image, a transmission map of the image, and determining, based on the transmission map, a visual contrast of the image. The processing device can generate information corresponding to the visibility measure.
A ram accelerator for accelerating a projectile is provided. The ram accelerator includes a first tube body having a first projectile bore, a second tube body having a second projectile bore axially aligned with the first projectile bore, and a baffle positioned between and operably coupling the first and second tube bodies. The baffle can have an annular baffle wall defining a central bore that is axially aligned with the first and second projectile bores, and a chamber arranged adjacent to the annular baffle wall. The chamber can extend radially outward from the central bore and the annular baffle wall can be configured to sweep a combustion wave relative to the projectile to prevent the combustion wave from traveling ahead of the projectile, leading to an unstart mechanism of the projectile in the ram accelerator.
F41A 1/02 - Hypervelocity missile propulsion using successive means for increasing the propulsive force, e.g. using successively initiated propellant charges arranged along the barrel length; Multistage missile propulsion
64.
USE OF A DOUBLE-STRANDED DNA CYTOSINE DEAMINASE FOR MAPPING DNA-PROTEIN INTERACTIONS
The disclosure provides methods and related compositions and kits for mapping DNA-protein interactions (DPIs). In one aspect, the disclosed methods comprise contacting a double stranded DNA molecule with a target protein; coupling a double stranded DNA deaminase (DddA) to the target protein, before or after the contacting step; permitting deamination of one or more cytosine residues in a domain of the double stranded DNA molecule by the DddA to provide one or more uracil residues, wherein the domain comprises a site of interaction between the target protein and the double stranded DNA molecule; determining the sequence of at least a portion of the double stranded DNA molecule; and detecting the domain comprising one or more cytosine deamination events. The method can be controlled by use of DddA inhibitors. The method can also incorporate use of inhibiting a base-excision repair pathway when addressing DPIs in a cellular context.
Systems and methods for analyzing particles flowing in a channel are described. In an embodiment, the channel is configured to flow a particle through a lumen of the channel, the channel defining an interrogation window configured to allow light to pass into and out of the lumen; a light engine comprising: a first light source positioned to output first excitation light onto a first portion of the channel in the interrogation window; and a second light source positioned to output second excitation light onto a second portion of the channel in the interrogation window separate from the first portion. In an embodiment, the systems include an emission fiber bundle comprising a first emission optical fiber and a second emission optical fiber, wherein a proximal end of first emission optical fiber and second emission optical fiber are arranged in an emission fiber bundle head.
Disclosed are polypeptides having an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of the amino acid sequences listed in Tables 1, 2, and 3, and heteropolymers formed from such polypeptides.
Endophyte inoculant compositions, methods of making such compositions, methods of using such compositions, and physiologically altered plants treating with such compositions are disclosed. The endophyte inoculant composition may include one or more of endophyte strains WW5, WW6, WW7, and PTD1, which promote plant mineral nutrient acquisition and uptake, vigor, health, growth, and yield when applied to non-native host plants.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
Nanoporous selective sol-gel ceramic membranes, selective-membrane structures, and related methods are described. Representative ceramic selective membranes include ion-conductive membranes (e.g., proton-conducting membranes) and gas selective membranes. Representative uses for the membranes include incorporation into fuel cells and redox flow batteries (RFB) as ion-conducting membranes.
C04B 35/14 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silica
C04B 35/10 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on aluminium oxide
C04B 35/48 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zirconium or hafnium oxides or zirconates or hafnates
B01D 71/82 - Macromolecular material not specifically provided for in a single one of groups characterised by the presence of specified groups, e.g. introduced by chemical after-treatment
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
Disclosed herein is a generalizable and intuitive strategy to photomodulate biomaterials in full 3D non-discrete patterns across cellular scales through grayscale image z-stack-guided multiphoton optical-lithography (GIZMO). In one aspect a method for optical patterning of a material is presented with the method comprising of initializing a laser, wherein the laser is focused through an objective that is movable in the x, y, and z directions; wherein a laser intensity is modulated while in motion or progress throughout a raster scanning.
Aspects of this disclosure describe a test strip that may include a sample input, assay circuitry, signaling circuitry, impedance circuitry, and/or energy harvesting circuitry. The sample input may be configured to receive a sample, such as a fluid sample. The assay circuitry of the test strip may be configured to perform an assay on at least a portion of the fluid sample. The signaling circuitry of the test strip may be configured to provide a modulated signal based on an output of the assay. The impedance circuitry of the test strip may be configured to present impedance changes to a touchscreen of an electronic device in accordance with the modulated signal. The test strip can then communicate data of the output of the assay (e.g., test results) to the electronic device using the touchscreen of the electronic device.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means
G06F 3/044 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means by capacitive means
71.
SCALABLE, SUBMICRON-RESOLUTION REPLICATION OF DNA ARRAYS
Systems, devices, kits, and methods for generating sequencing libraries for detecting low-frequency variants, and for distinguishing low-frequency biological variants from low-frequency technical variants, with duplex sequencing. Methods include introducing multiple levels of indices to cellular nucleic acid molecules of cells of a biological sample to enable differentiation of a cell from other cells of the sample, differentiation of a double-stranded cellular nucleic acid molecule from others of the cell, and differentiation of the individual strands of the double-stranded cellular nucleic acid molecule. Technical variants introduced during the workflow are identified as such due to their occurrence in only one family of duplex strands of the sequencing library, and biological variants are detected due to their occurrence in both families of duplex strands of the sequencing library. Detected biological variants can be linked with a particular cell of the biological sample in a high-throughput manner.
A method includes accessing training images and labels, where the training images depict fluorescence from samples and the labels indicate pH levels of the samples. The method also includes training a computational model, using the training images and the labels, to determine pH levels on tissue inside of a patient's mouth depicted by captured images. Another method includes generating one or more images of tissue inside of a patient's mouth, where the one or more images depict fluorescence from the tissue. The method also includes determining a pH level on the tissue using a model and pixel intensities of the one or more images, and generating an indication of the pH level on the tissue.
Techniques for treating acute ischemic stroke, and other neurological pathologies, are described herein. An example method includes identifying a portion of a brain including overactive neurons and outputting an electrical signal to at least one stimulation electrode disposed away from the portion of the brain by a distance in a range of about 0.5 mm to 1 cm. The electrical signal includes a low-frequency component including bursts having a frequency in a range of about 2 Hz to about 10 Hz. The electrical signal includes a high-frequency component comprising pulses having a frequency in a range of about 200 Hz to about 2 kHz.
Disclosed are methods and related compositions for genomic editing. In one aspect, methods of editing double stranded DNA (dsDNA) use first and second editing complexes specific for first and second target sequences on the sense and antisense strands of the dsDNA molecule, respectively. Each editing complex comprises an extended guide RNA associated with a fusion editor protein, which comprises a functional nickase domain and a functional reverse transcriptase domain. The respective guide RNAs guide their associated fusion editor proteins to the dsDNA, which implement single stranded breaks on opposite strands of the dsDNA. The respective reverse transcriptase domains generate 3′ overhangs. Repair of the dsDNA excises the portion of dsDNA disposed between the two single-stranded breaks. A variety of configurations and applications of the method are disclosed, providing flexible, facile, efficient, and precise methods to impose genetic manipulations.
A modular expansion joint (e.g., for a bridge) can include an upper expansion support exhibiting a hinge design arranged for pivoting about a vertically extending axis. The upper expansion support underneath may be accompanied by a moisture seal and/or a lower expansion support. The modular expansion joint may include two beams that may be spaced apart by a gap into which the upper expansion support etc. can be received. Each of the two beams can include a top flange defining a top surface and a web extending from the flange. The upper expansion support can be positioned between the top flanges, while the lower expansion support can be positioned between the webs, for example. The upper expansion support may provide a continuation of a travel surface across the beam tops and may accordingly reduce pressure spikes and/or noise from tires moving across the travel surface.
Polypeptide are providing that are at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-37, cyclic homo-oligomers of the polypeptides, and uses thereof.
Polypeptides that comprise axle or ring components of protein nanomachines, and kits and nanomachines including such polypeptides are disclosed herein.
BIO-IMPEDANCE SENSING FOR GESTURE INPUT, OBJECT RECOGNITION, INTERACTION WITH PASSIVE USER INTERFACES, AND/OR USER IDENTIFICAITON AND/OR AUTHENTICATION
This disclosure describes systems, apparatuses, and methods that utilize electric field sensing in an antenna topology. In some embodiments, the systems, apparatuses, and methods use a sensing modality, such as bio-impedance sensing, to detect and/or determine one or more user activities. The bio-impedance sensing can be used for held-object or touched- object recognition, gesture input recognition (e g., recognition of one-handed gestures, two- handed gestures, etc.), user interface (UI) interaction by utilizing electrically passive components, and/or biometric identification and/or authentication.
A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G06F 3/046 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means by electromagnetic means
G01S 13/89 - Radar or analogous systems, specially adapted for specific applications for mapping or imaging
A61B 5/053 - Measuring electrical impedance or conductance of a portion of the body
Seattle Children's Hospital dba Seattle Children's Research Institute (USA)
University of Washington (USA)
Inventor
Zhao, Yongdong
Scheck, Joshua
Partridge, Savannah Corrina
Iyer, Ramesh S.
Thapa, Mahesh
Biswas, Sr., Debosmita
Bhide, Nivrutti Vasudev
Cain, Kevin Charles
Pyke, Jason Michael
Abstract
A method for determining a presence of arthritis in a patient, including obtaining a first image of a patient's joint, wherein the first image is a visible light image, obtaining a second image of the patient's joint, wherein the second image is a thermal light image, determining an outline of the patient's joint from the first image, determining an outline of a reference area from the first image, wherein the patient's joint is adjacent to the reference area, determining a first representative topological temperature within the outline of the patient's joint of the first image from the second image, determining a second representative topological temperature within the outline of the reference area of the first image from the second image, comparing the first representative topological temperature and the second representative topological temperature; and determining a likelihood of the presence of arthritis within the patient's joint.
H04N 23/23 - Cameras or camera modules comprising electronic image sensors; Control thereof for generating image signals from infrared radiation only from thermal infrared radiation
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Systems and methods for capturing and rendering light fields for head-mounted displays are disclosed. A mediated-reality visualization system includes a head-mounted display assembly comprising a frame configured to be mounted to a user's head and a display device coupled to the frame. An imaging assembly separate and spaced apart from the head-mounted display assembly is configured to capture light-field data. A computing device in communication with the imaging assembly and the display device is configured to receive light-field data from the imaging assembly and render one or more virtual cameras. Images from the one or more virtual cameras are presented to a user via the display device.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
H04N 13/254 - Image signal generators using stereoscopic image cameras in combination with electromagnetic radiation sources for illuminating objects
H04N 13/344 - Displays for viewing with the aid of special glasses or head-mounted displays [HMD] with head-mounted left-right displays
H04N 13/243 - Image signal generators using stereoscopic image cameras using three or more 2D image sensors
H04N 13/282 - Image signal generators for generating image signals corresponding to three or more geometrical viewpoints, e.g. multi-view systems
De novo designed proteins with binding activity are disclosed, which were designed starting from a desired functional site and jointly filling in the missing sequence and structure needed to complete the protein, and uses of the binding proteins.
A method includes irradiating, via a heating element, a first portion of a workpiece with electromagnetic radiation having an oscillation frequency within a range of 1 MHz to 300 MHz, thereby heating the first portion of the workpiece. The method also includes applying a pressure to the first portion of the workpiece via an actuator and making a determination that a condition of the first portion or the actuator satisfies one or more criteria. The method also includes moving the workpiece and/or the actuator, in response to making the determination, such that a second portion of the workpiece is aligned with the actuator. A system includes one or more processors, an infrared camera, an actuator, a platform, a motor, a power source, a load cell, and a computer readable medium storing instructions that, when executed by the one or more processors, cause the system to perform the method.
B29C 65/04 - Dielectric heating, e.g. high-frequency welding
B29C 65/14 - Joining of preformed parts; Apparatus therefor by heating, with or without pressure using wave energy or particle radiation
B29C 65/34 - Joining of preformed parts; Apparatus therefor by heating, with or without pressure using heated elements which remain in the joint, e.g. "verlorenes Schweisselement"
85.
USING ADAPTIVE SEQUENCING AND HARDWARE-ACCELERATED STORAGE TO ACCELERATE METAGENOMIC SAMPLE ANALYSIS
In some embodiments, a computer-implemented method of predicting a molecule type using segment read information is provided. A computing device receives a segment read for a molecule. The computing device determines one or more k-mers for the segment read. For each k-mer of the one or more k-mers, the computing device retrieves one or more records from a hash table using the k-mer as a key, wherein each record includes an identifier associated with a molecule type. The computing device generates a molecule type prediction for the segment read based on the identifiers of the retrieved one or more records.
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
G16B 50/30 - Data warehousing; Computing architectures
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G06F 16/13 - File access structures, e.g. distributed indices
G06F 16/00 - Information retrieval; Database structures therefor; File system structures therefor
86.
DRUG-LIKE MOLECULES AND METHODS FOR THE THERAPEUTIC TARGETING OF MICRORNA-21
Compounds and compositions for inhibiting miR-21, methods for inhibiting miR-21 in a subject, and methods for treating a disease or condition treatable by decreasing the level of microRNA miR-21 in a subject.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Methods and systems for bonding of structures using high intensity focused ultrasound are disclosed. In one embodiment, a method for assembling components using ultrasound includes: positioning a first part of an assembly with respect to a second part of the assembly; heating a region of the assembly by focusing the ultrasound from an ultrasound transducer to the region of the assembly; and, in response to heating the region of the assembly, bonding the first part of the assembly to the second part of the assembly.
Systems and methods for optical computation and acousto-optic modulation are described. The systems and methods comprise acousto-optic modulators with reflectors and transducers used for actuation and modulation of mechanical waves. The systems further comprise multilayer optical computing systems incorporating arrays of acousto-optic modulators. In an embodiment, the acousto-optic modulator comprises a substrate; an optical layer coupled to a first portion of the substrate, the optical layer comprising: a free-standing portion shaped and positioned to define a gap between the free-standing portion of the optical layer and the substrate; and a rib waveguide comprising a photonic crystal, formed in the free-standing portion; and a piezoelectric transducer mechanically coupled to the free-standing portion, wherein the piezoelectric transducer comprises a piezoelectric material and a plurality of conductive electrodes disposed in electrically conductive contact with the piezoelectric material, the plurality of conductive electrodes extending from a base portion of the piezoelectric transducer.
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
G02F 1/03 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on ceramics or electro-optical crystals, e.g. exhibiting Pockels or Kerr effect
G02F 1/035 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on ceramics or electro-optical crystals, e.g. exhibiting Pockels or Kerr effect in an optical waveguide structure
89.
DIAGNOSTIC SYSTEM INCLUDING A BASE AND SINGLE-USE FLUIDIC DISPOSABLES
A diagnostic system for analyzing an analyte is described. In an embodiment the diagnostic system includes a fluidic single-use disposable and a base cooperatively coupleable thereto. In an embodiment, the fluidic single-use disposable comprises a sample processing subcomponent configured to receive a sample and emit signal light if the sample comprises an analyte; a fluidic single-use disposable housing encompassing the sample processing subcomponent, the fluidic single-use disposable housing comprising: a first major side; and a fluidic single-use disposable viewing window disposed in the first major side and positioned to allow light emitted from the sample processing subcomponent to pass through the fluidic single-use disposable viewing window. In an embodiment, the base comprises a base housing comprising: a first major side shaped to cooperatively couple with the first major side of the fluidic single-use disposable housing.
G01N 21/29 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using visual detection
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
A nanoparticle for targeted siRNA delivery comprising an iron oxide core and a chitosan-polyethylene glycol-polyethylenimine copolymer coating surrounding the core, chlorotoxin covalently coupled to the coating, and an siRNA reversibly associated to the coating by non-covalent interaction. Methods for making the nanoparticle and methods for using the nanoparticle to suppress the expression of O6-methylguanine-DNA methyltransferase (MGMT), treating brain cancer, and killing cancer stem cells.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The present disclosure describes a method for preparing a paper nanocomposite, including: continuously providing a first suspension that includes lignocellulosic pulp fibers, cellulose nanofibrils, carbon nanotubes, and a cationic surfactant; continuously adding a second suspension to the first suspension to provide a slurry, the second suspension includes lignocellulosic pulp fibers, cellulose nanofibrils, carbon nanotubes, and an anionic surfactant; depositing the slurry comprising the first and second suspensions onto the substrate; and dewatering the slurry to form the paper nanocomposite.
The present disclosure provides a device including a cylindrical member having a distal end and a proximal end. The cylindrical member includes a plurality of longitudinal slits positioned between the distal end and the proximal end to thereby create a plurality of strips positioned between the plurality of longitudinal slits. The device also includes an elongated hollow tube having a distal end and a proximal end. The elongated hollow tube is coupled to the proximal end of the cylindrical member. The device also includes a rod having a distal end and a proximal end.
In some embodiments, a method of controlling a follower vehicle in a vehicle platoon is provided. A follower vehicle controller in the follower vehicle determines a centralized control command based on centralized control information. The follower vehicle controller determines a local control command based on local sensing information using a delayed self reinforcement (DSR) technique. The follower vehicle controller applies weights to the centralized control command and the local control command. The follower vehicle controller combines the weighted centralized control command and the weighted local control command to create a combined control command. The follower vehicle controller uses the combined control command to control a speed of the corresponding follower vehicle.
G01S 19/40 - Correcting position, velocity or attitude
B60W 30/16 - Control of distance between vehicles, e.g. keeping a distance to preceding vehicle
H04W 4/46 - Services specially adapted for particular environments, situations or purposes for vehicles, e.g. vehicle-to-pedestrians [V2P] for vehicle-to-vehicle communication [V2V]
G05D 1/02 - Control of position or course in two dimensions
G01S 13/93 - Radar or analogous systems, specially adapted for specific applications for anti-collision purposes
Disclosed herein are embodiments of a hydrothermal reactor, such as a downflow hydrothermal reactor and methods of using the same. Also disclosed herein are system embodiments comprising the hydrothermal reactor. Method embodiments disclosed herein facilitate determining operation parameters for the hydrothermal reactor that give rise to efficient feedstock conversion to products while maintaining integrity of the reactor (e.g., avoiding corrosion) and providing safe operating conditions. The disclosed reactor and system embodiments facilitate situations where small scale and/or remote destruction of feedstocks (e.g., chemical warfare agents and/or environmental toxins) is needed.
B01J 19/26 - Nozzle-type reactors, i.e. the distribution of the initial reactants within the reactor is effected by their introduction or injection through nozzles
B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
C02F 1/74 - Treatment of water, waste water, or sewage by oxidation with air
Disclosed are organic electrooptic materials. The electrooptic materials are functionalized by novel methods and structures. The electrooptic materials are structured with a head and a tail where the head and tail sequentially assemble into a non-centrosymmetric ordered array. The electrooptic materials are further structured in covalently bonded dimer pairs where one of the pairs is zwitterionic. The non-centrosymmetric ordered array bonds directly to electrodes which allows for efficient application of the electric field. The organic electrooptic materials disclosed offer greater hyperpolarizability, greater bandwidth, reduced operating voltage with less optical loss.
The present disclosure provides peptides, chimeric molecular constructs, and compositions thereof, that can bind volatile organic compounds (VOCs) and be utilized to distinguish VOC profiles, e.g., indicative of disease, as well as related methods. A VOC-based gas sensing approach described in the present specification can be an effective screening tool, due, at least in part, to its speed, ease of use, sensitivity, specificity, and because it does not rely on binding to specific nucleic acid fragments or proteins to function.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Use of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), mavelertinib, as a treatment for giardiasis in humans, veterinary animals, and livestock is described. Mavelertinib demonstrates a high selectivity index for Giardia compared to mammalian cells and therefore provides an effective and safe treatment for giardiasis. Therapeutically effective amounts for oral administration are also described.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
